Men enrolled in the study are assigned to each APHRODITE group. Group 2,3,4 are treated with either gonadotropin preparations or clompihene-citrate (except group 4). The type of the treatment (gonadotropin vs clomiphene) is randomized. After treatment, hormonal measurements, spermiogram and DNA fragmentation tests are repeated, allowing for analysis of the outcome.
Our research involves male partners of couples suffering from male infertility. After a comprehensive andrological examination, based on the test results, the men are classified into so-called "APHRODITE" categories. Based on these categories, half of the patients are given so-called gonadotropin treatment (the exact treatment depends on the type of category), which involves subcutaneous injections several times a week for a total of 12 weeks. The other half of the patients are recommended oral tablets containing the active ingredient clomiphene citrate, also for 12 weeks. It is important that both types of therapy (gonadotropin and clomiphene citrate) are effective treatments in certain cases of male infertility, according to the literature, so all patients participating in the research receive effective treatment. However, it is decided who receives which treatment by randomization. After the 12-week treatment, a control sperm analysis and a DNA fragmentation test are performed to determine the success of the treatment (changes in sperm analysis results and DNA fragmentation index). The improvement in sperm parameters will be determined in the two treatment regimens, the rate of fertilized eggs in subsequent assisted reproduction cycles, the quality of the resulting embryos, and the rate of pregnancies and subsequent losses. The results of the two therapeutic modalities will be compared, so that it can be decided which treatment method is more effective. The research process is essentially as follows: 1. information, examination 2. classification into the APHRODITE category based on the results 3. randomization (gonadotropin or clomiphene citrate) 4. injection treatment for patients in the gonadotropin group, with therapy according to the APHRODITE category for 12 weeks 5. tablet treatment for patients in the clomiphene citrate group for 12 weeks 6. control spermiogram and DNA fragmentation 7. analysis of the results of subsequent assisted reproduction procedures
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
500
recFSH 3x150NE sc weekly for 12 weeks
hCG 2x5000NE sc weekly for 12 weeks
clompihene-citrate 50mg p.o. daily for 12 weeks
Reproductive Medicine Centre, Department of Obstetrics and Gynecology, University of Szeged
Szeged, Hungary
sperm DNA fragmentation
sperm DNA fragmentation Index (%), high DNA stainability (%) are measured and compared to the pretreatment values. Lower numbers mean improvement in this outcome.
Time frame: 12 weeks of treatment
ejaculate volume
ejaculate volume (ml) after treatment are assessed and compared to the pretreatment values. Higher number means improvement in this outcome.
Time frame: 12 weeks of treatment
sperm concentration
Sperm concentrations (million/ml) before and after the treatment are compared. Higher number means improvement in this outcome.
Time frame: 12 weeks
sperm motility
Sperm total motility (%), progressive motility (%) after the treatment are compared to the pretreatment values. Higher numbers mean improvement in this outcome.
Time frame: 12 weeks
total sperm count, total functional sperm count
Total sperm count (million) = ejaculate volume (ml) x sperm concentration (million/ml) and total functional sperm count (million) = total sperm count x progressive motility x 100 are compared before and after the treatment. Higher numbers mean improvement in this outcome.
Time frame: 12 weeks
Sperm morphology
Percent of normal sperm morphology (%) is counted after the treatment and compared to the pretreatment result. Higher number mean improvement in this outcome.
Time frame: 12 weeks
gonadotropin vs clomiphene - total sperm count, total functional sperm count
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm count (million) and total functional sperm count (million)
Time frame: 12 weeks of treatment
gonadotropin vs clomiphene - DNA fragmentation
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in DNA fragmentation Index (%) and high DNA stainability (%)
Time frame: 12 weeks
Gonadotropin vs clomiphene - sperm total motility, progressive motility
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm motility (%) and progressive sperm motility (%)
Time frame: 12 weeks
gonadotropin vs clomiphene - normal sperm morphology
in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in normal sperm morphology (%)
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.